[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"new-onset-generalized-myasthenia-gravis-gmg\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:new-onset-generalized-myasthenia-gravis-gmg":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100585964",false,"NCT06909214","A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)","A Phase 4, Open-Label, Prospective, Single-Group, Multicenter Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adult Participants With New-Onset Generalized Myasthenia Gravis","ADAPT-EARLY","Inclusion Criteria:\n\n* Is at least 18 years when signing the ICF\n* Has been diagnosed with gMG of MGFA class II, III, or IV\n* Is seropositive for AChR-Ab\n* Is treatment-naive for gMG or has been administered AChEI for the treatment of gMG\n* Had onset of generalized MG signs and\u002For symptoms within 12 months before screening; candidates who also had onset of ocular MG signs and\u002For symptoms within 24 months before screening may be enrolled in the study\n* Has an MG-ADL score ≥5\n\nExclusion Criteria:\n\n* gMG diagnosis of MGFA class I or V\n* Underwent a thymectomy prior to screening, except thymectomy for treatment of nonmalignant thymoma prior to the gMG diagnosis\n* Prior or current use of any of any systemic corticosteroid therapy or nonsteroidal immunosuppressive therapy for the treatment of gMG","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The main purpose of this study is to measure how well adults with new-onset gMG (which means they've had generalized disease signs and\u002For symptoms for less than 1 year) respond to treatment with efgartigimod PH20 SC. The study consists of a treatment period of 51 weeks. The study duration for each participant will be approximately 58 weeks.",[26],"New Onset Generalized Myasthenia Gravis (gMG)","RECRUITING","2026-03-09",{"date":30,"type":31},"2026-03-10","ACTUAL",{"date":33,"type":31},"2025-04-17",{"date":35,"type":20},"2027-05",{"name":37,"class":38},"argenx","INDUSTRY",18,""]